1. |
Therapies for bipolar disorder reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Pioglitazone the answer to managing type 2 diabetes in Europe? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 5-7
Laura Hunt,
Preview
|
|
摘要:
Type 2 diabetes mellitus is becoming a serious health problem in Europe, proving a constant drain on healthcare resources, with total direct treatment costs associated with the disease consuming up to 10% of national healthcare budgets. Pioglitazone ['Actos'], one of the new thiazolidinedione class of oral antidiabetic drugs, has recently been approved for use in Europe in combination with a sulphonylurea or metformin in patients with type 2 diabetes. Five studies presented at the 4th Annual ISPOR*Meeting [Cannes, France; November 2001] evaluated the cost effectiveness of pioglitazone in the management of patients with type 2 diabetes in several European countries.1-5All five studies were conducted by investigative teams from Eli Lilly and Company and the Institute for Medical Informatics and Biostatistics, Switzerland, and received financial support from Eli Lilly and Company, UK.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Ghrelin has potentially beneficial cardiovascular effects |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Ranolazine promising in combination therapy for severe angina |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 9-10
Larry Prescott,
Preview
|
|
摘要:
Ranolazine, the first of a new class of compounds known as partial fatty acid oxidation (pFOX) inhibitors, may offer a new therapeutic approach for chronic angina pectoris. New study data have shown that, compared with standard antianginal therapy, the addition of ranolazine significantly increased exercise time by 24 seconds. The efficacy of ranolazine when used in combination with the β-blocker atenolol, or the calcium antagonists diltiazem or amlodipine, was demonstrated in results from the phase III Combination Assessment of Ranolazine in Stable Angina (CARISA) trial presented at the Scientific Sessions of the American Heart Association [Anaheim, US; November 2001]. If approved, ranolazine will represent the first new class of antianginal agents in 20 years.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1322,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|